药理学和生活方式干预以调节心力衰竭中的表观基因组
Ludovica Di Venanzio1, Natalia Atzemian1, Bennet Y Weber2
1Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland.
Heart failure clinics
|November 20, 2025
概括
表观遗传机制在心力衰竭 (HF) 的发展中起着至关重要的作用. 通过药物和生活方式干预来准这些表观遗传变化,为治疗HF提供了新的希望,特别是用保存喷射分数 (HFpEF) 治疗心力衰竭.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 心力衰竭 (HF) 是一个重要的全球健康问题,死亡率高.
- 用保存喷射分数 (HFpEF) 治疗HF的治疗选择有限.
- 表观遗传机制越来越多地与HF病变产生有关.
研究的目的:
- 探索表观遗传机制在HF中的作用.
- 确定HF的新型治疗点.
- 研究生活方式因素对HF表观遗传学的影响.
主要方法:
- 对高频率表观遗传学当前文献的综述.
- 对DNA甲基化,基因素修饰和非编码RNA角色的分析.
- 对药理学和生活方式干预措施的检查.
主要成果:
- 表观遗传过程在高频中整合了遗传和环境因素.
- 药理学药剂和重新定位的药物显示出对表观遗传疗法的希望.
- 饮食和运动等生活方式的修改会影响HF的表观基因组.
结论:
- 表观遗传修饰是HF发展和进展的关键驱动因素.
- 针对表观遗传机制,为HF提供了新的治疗策略.
- 个性化,非药物干预措施具有管理高频率的潜力.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
Cardiomyopathy V: Interprofessional Care
316
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
316
Heart Failure VI: Adjunct Therapies
239
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239
Heart Failure VII: Nursing Interventions
400
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
400
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301


